行情

SCYX

SCYX

SCYNEXIS
NASDAQ

实时行情|Nasdaq Last Sale

0.9878
+0.0051
+0.52%
盘后: 1.010 +0.022 +2.25% 17:42 01/24 EST
开盘
0.9900
昨收
0.9827
最高
1.020
最低
0.9814
成交量
49.71万
成交额
--
52周最高
1.900
52周最低
0.6700
市值
9,507.71万
市盈率(TTM)
-1.3638
分时
5日
1月
3月
1年
5年

分析师评级

7位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

SCYX 新闻

  • 波音777X完成首飞:明年起开始交付 未来世界最大客机
  • IT之家.3小时前
  • 瑞幸咖啡捐赠1000万元 助力疫情防控
  • 新浪科技.3小时前
  • 法国撤侨方案:大巴先送至长沙隔离14日
  • 观察者网.4小时前
  • 贝索斯手机遭入侵 手机窃听再次成为焦点
  • 新浪科技.4小时前

更多

所属板块

制药
-1.85%
制药与医学研究
-2.00%

热门股票

名称
价格
涨跌幅

SCYX 简况

SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains. The Company also conducts additional in vitro and in vivo studies to further characterize the spectrum of activity of SCY-078. The Company has completed multiple Phase I studies with the oral formulation of SCY-078 and is conducting its first Phase I study with the IV formulation of SCY-078. The Company has also developed a platform for cyclophilin inhibitors, which has two clinical stage compounds, such as SCY-635 and SCY-641.
展开

Webull提供SCYNEXIS Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。